Literature DB >> 10966157

Therapeutic proteins: a comparison of chemical and biological properties of uricase conjugated to linear or branched poly(ethylene glycol) and poly(N-acryloylmorpholine).

O Schiavon1, P Caliceti, P Ferruti, F M Veronese.   

Abstract

Uricase from Bacillus fastidiosus (UC) was covalently linked to linear PEG (PEG-1) (Mw 5 kDa), branched PEG (PEG-2) (Mw 10 kDa) and to poly(N-acryloylmorpholine) (PAcM) (Mw 6 kDa). The conjugation of UC with linear PEG and PAcM was accompanied by complete loss of enzymatic activity but, if uric acid as site protecting agent was included in the reaction mixture, the conjugate protein retained enzymatic activity. On the other hand, the modification with PEG-2 gave a conjugate that also maintained enzymatic activity in the absence of any active site protection. This behaviour must be related to hindrance of the branched polymer in reaching the enzyme active site. The UC conjugates exhibited increased resistance to proteolytic digestion while minor variations in the inhibitory constant, optimal pH, heat stability, affinity for substrate, were observed. Pharmacokinetic investigations in mice demonstrated increased residence time in blood for all the conjugates as compared with native uricase. Uricase conjugated with linear PEG was longer lasting in blood UC derivative, followed by branched PEG and the PAcM conjugates. Unconjugated uricase was rapidly removed from circulation. All these data are in favour of the use of the less known amphiphilic polymer PAcM as an alternative to PEGs in modification of enzymes devised for therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10966157     DOI: 10.1016/s0014-827x(00)00031-8

Source DB:  PubMed          Journal:  Farmaco        ISSN: 0014-827X


  12 in total

1.  Lactoferrin conjugated with 40-kDa branched poly(ethylene glycol) has an improved circulating half-life.

Authors:  Yasuhiro Nojima; Yosuke Suzuki; Kazuhiro Yoshida; Fumiko Abe; Tuneo Shiga; Takashi Takeuchi; Akihiko Sugiyama; Hirohiko Shimizu; Atsushi Sato
Journal:  Pharm Res       Date:  2009-06-25       Impact factor: 4.200

2.  Advances in Polymer and Polymeric Nanostructures for Protein Conjugation.

Authors:  Daniella C González-Toro; S Thayumanavan
Journal:  Eur Polym J       Date:  2013-10-01       Impact factor: 4.598

3.  Isolation of a novel uric-acid-degrading microbe Comamonas sp. BT UA and rapid biosensing of uric acid from extracted uricase enzyme.

Authors:  Tanushree Ghosh; Priyabrata Sarkar
Journal:  J Biosci       Date:  2014-12       Impact factor: 1.826

4.  Loading PEG-catalase into filamentous and spherical polymer nanocarriers.

Authors:  Eric A Simone; Thomas D Dziubla; Evguenia Arguiri; Vanessa Vardon; Vladimir V Shuvaev; Melpo Christofidou-Solomidou; Vladimir R Muzykantov
Journal:  Pharm Res       Date:  2008-10-28       Impact factor: 4.200

5.  Improved pharmacokinetics and reduced antibody reactivity of lysostaphin conjugated to polyethylene glycol.

Authors:  Scott Walsh; Anjali Shah; James Mond
Journal:  Antimicrob Agents Chemother       Date:  2003-02       Impact factor: 5.191

6.  Impact of large aggregated uricases and PEG diol on accelerated blood clearance of PEGylated canine uricase.

Authors:  Chun Zhang; Kai Fan; Xuefeng Ma; Dongzhi Wei
Journal:  PLoS One       Date:  2012-06-26       Impact factor: 3.240

7.  Improved biological properties and hypouricemic effects of uricase from Candida utilis loaded in novel alkaline enzymosomes.

Authors:  Qun-You Tan; Jing-Qing Zhang; Na Wang; Hong Yang; Xiaoling Li; Hua-Rong Xiong; Jian-Yong Wu; Chun-Jing Zhao; Hong Wang; Hua-Feng Yin
Journal:  Int J Nanomedicine       Date:  2012-07-23

Review 8.  Widening and Elaboration of Consecutive Research into Therapeutic Antioxidant Enzyme Derivatives.

Authors:  Alexander V Maksimenko
Journal:  Oxid Med Cell Longev       Date:  2016-04-11       Impact factor: 6.543

9.  Uricase alkaline enzymosomes with enhanced stabilities and anti-hyperuricemia effects induced by favorable microenvironmental changes.

Authors:  Yunli Zhou; Mi Zhang; Dan He; Xueyuan Hu; Huarong Xiong; Jianyong Wu; Biyue Zhu; Jingqing Zhang
Journal:  Sci Rep       Date:  2016-01-29       Impact factor: 4.379

10.  Generation of therapeutic protein variants with the human serum albumin binding capacity via site-specific fatty acid conjugation.

Authors:  Jinhwan Cho; Sung In Lim; Byung Seop Yang; Young S Hahn; Inchan Kwon
Journal:  Sci Rep       Date:  2017-12-21       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.